OPKO Health, Inc. Income (Loss) from Continuing Operations, Per Diluted Share
OPKO Health, Inc. (OPK) reported Income (Loss) from Continuing Operations, Per Diluted Share of $0.03 per share for the 3-month period ending 2011-12-31, per its 10-K filed 2013-03-18.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare · last filed 2013-03-18
- OPKO Health, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2011-12-31 was $0.03.
- OPKO Health, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2011-09-30 was -$0.02.
- OPKO Health, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2011-06-30 was -$0.02.
- OPKO Health, Inc. income (loss) from continuing operations, per diluted share for the quarter ending 2011-03-31 was -$0.02.
| Period end | Income (Loss) from Continuing Operations, Per Diluted Share 3 month |
|---|---|
| 2011-12-31 | $0.03 10-K · filed 2013-03-18 |
| 2011-09-30 | -$0.02 10-K · filed 2013-03-18 |
| 2011-06-30 | -$0.02 10-K · filed 2013-03-18 |
| 2011-03-31 | -$0.02 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |